Sars-cov-2 infection risk assessment method
AssigneesViroGates A/S, Copenhagen University Hospital Amager and Hvidovre
InventorsJesper Eugen-Olsen, Ove Andersen
Life of this patent
Estimating the term…
Abstract
Increased levels of soluble urokinase-type plasminogen activator receptor (suPAR), particularly a plasma level of over 4.75 ng/ml or 6 ng/nl, have been found to be a predictor of whether a subject with COVID-19 symptoms and/or SARS-CoV-2 infection will require oxygen supplementation.
Claims9
A method of assessing whether a subject who has COVID-19 symptoms and/or SARS-CoV-2 infection requires or is likely to require oxygen supplementation, particularly invasive ventilation (respirator), the method comprising determining whether the subject has a suPAR plasma level of over 4.75 ng/ml, preferably over 6 ng/ml.
A method according to any of the preceding claims wherein the plasma level is determined directly by assaying a plasma sample or indirectly by assaying a serum or urine level.
A method according to any of the preceding claims wherein the suPAR level is determined by an immunodiagnostic method.
A method of determining the likelihood of death within a period of time of a subject who has COVID-19 symptoms and/or SARS-CoV-2 infection and is being treated with, or is being considered for treatment with, assisted respiration, the method comprising determining whether the subject has a suPAR plasma level of over 4.75 ng/ml, preferably over 6 ng/ml.
A method of assessing whether a subject who has COVID-19 symptoms and/or SARS-CoV-2 infection may be discharged from hospital or not admitted to hospital, the method comprising determining the subject's suPAR level, such that
- (i) a subject having a suPAR plasma level of below 4.75 ng/ml is discharged or is not admitted, and
- (ii) a subject having a suPAR plasma level of 6 ng/ml or above is not discharged or is admitted.
Dependencies are inferred from the claim text.